Works matching IS 00070963 AND DT 2022 AND VI 186 AND IP 6


Results: 47
    1

    Issue Information.

    Published in:
    British Journal of Dermatology, 2022, v. 186, n. 6, p. i, doi. 10.1111/bjd.20505
    Publication type:
    Article
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22

    Editor's Choice.

    Published in:
    British Journal of Dermatology, 2022, v. 186, n. 6, p. vi, doi. 10.1111/bjd.21888
    Publication type:
    Article
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37

    Children with atopic dermatitis show increased activity of β‐glucocerebrosidase and stratum corneum levels of glucosylcholesterol that are strongly related to the local cytokine milieu.

    Published in:
    British Journal of Dermatology, 2022, v. 186, n. 6, p. 988, doi. 10.1111/bjd.20979
    By:
    • Kezic, Sanja;
    • McAleer, Maeve A.;
    • Jakasa, Ivone;
    • Goorden, Susan M.I.;
    • der Vlugt, Karen Ghauharali‐van;
    • Beers‐Stet, Femke S.;
    • Meijer, Judith;
    • Roelofsen, Jeroen;
    • Nieman, Monique M.;
    • van Kuilenburg, André B.P.;
    • Irvine, Alan D.
    Publication type:
    Article
    38
    39
    40
    41

    Issue Information.

    Published in:
    British Journal of Dermatology, 2022, v. 186, n. 6, p. i, doi. 10.1111/bjd.21664
    Publication type:
    Article
    42
    43

    Validation of an Oral Disease Severity Score for use in oral lichen planus.

    Published in:
    British Journal of Dermatology, 2022, v. 186, n. 6, p. 1045, doi. 10.1111/bjd.20968
    By:
    • Ormond, Martyn;
    • McParland, Helen;
    • Thakrar, Priya;
    • Donaldson, Ana;
    • Andiappan, Manoharan;
    • Cook, Richard J.;
    • Escudier, Michael;
    • Higham, Jon;
    • Hullah, Esther;
    • McMillan, Roddy;
    • Taylor, Jennifer;
    • Shirlaw, Pepe J.;
    • Challacombe, Stephen J.;
    • Setterfield, Jane F.
    Publication type:
    Article
    44
    45
    46
    47

    Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial*.

    Published in:
    British Journal of Dermatology, 2022, v. 186, n. 6, p. 942, doi. 10.1111/bjd.20971
    By:
    • Augustin, Matthias;
    • Reich, Kristian;
    • Yamauchi, Paul;
    • Pinter, Andreas;
    • Bagel, Jerry;
    • Dahale, Swapnil;
    • You, Ruquan;
    • Bruin, Gerard;
    • Djimopoulos, Jimena;
    • Paguet, Bertrand;
    • Charef, Pascal;
    • Patekar, Manmath;
    • Keefe, Deborah
    Publication type:
    Article